Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial
The myeloproliferative neoplasm, myelofibrosis, is a morbid and frequently fatal illness encompassing primary myelofibrosis, and end-stage essential thrombocythemia and polycythemia. Bevacizumab (15 mg/kg intravenous (i.v.) every 21 days) was tested in a phase II international trial conduct...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2013-06-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/12126 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850112668628680704 |
|---|---|
| author | Ruben A. Mesa Richard T. Silver Srdan Verstovsek John Mascarenhas Craig M. Kessler Damiano Rondelli Judy D. Goldberg Roberto Marchioli Erin P. Demakos Lewis R. Silverman Ronald Hoffman |
| author_facet | Ruben A. Mesa Richard T. Silver Srdan Verstovsek John Mascarenhas Craig M. Kessler Damiano Rondelli Judy D. Goldberg Roberto Marchioli Erin P. Demakos Lewis R. Silverman Ronald Hoffman |
| author_sort | Ruben A. Mesa |
| collection | DOAJ |
| description |
The myeloproliferative neoplasm, myelofibrosis, is a morbid and frequently fatal illness encompassing primary myelofibrosis, and end-stage essential thrombocythemia and polycythemia. Bevacizumab (15 mg/kg intravenous (i.v.) every 21 days) was tested in a phase II international trial conducted by the Myeloproliferative Disorders Research Consortium. Thirteen patients were enrolled in the first stage of this 2-stage trial. Among the 11 patients who received therapy, only 3 received more than 4 cycles of therapy; none of the patients achieved an objective response. Furthermore, significant toxicity, not directly related to the vascular or gastrointestinal events typically associated with the anti-VEGF monoclonal antibody preparation in other disease states, was observed. Lack of objective responses coupled with toxicity led to the decision to terminate the study early. If future studies incor- porate bevacizumab in combination therapy for myelofibrosis, more modest doses should be considered. (clinicaltrials.gov Identifier 00667277).
|
| format | Article |
| id | doaj-art-2b52f72c37e24126b7a345febd0d84f5 |
| institution | OA Journals |
| issn | 0390-6078 1592-8721 |
| language | English |
| publishDate | 2013-06-01 |
| publisher | Ferrata Storti Foundation |
| record_format | Article |
| series | Haematologica |
| spelling | doaj-art-2b52f72c37e24126b7a345febd0d84f52025-08-20T02:37:19ZengFerrata Storti FoundationHaematologica0390-60781592-87212013-06-0198910.3324/haematol.2012.083337Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium TrialRuben A. Mesa0Richard T. Silver1Srdan Verstovsek2John Mascarenhas3Craig M. Kessler4Damiano Rondelli5Judy D. Goldberg6Roberto Marchioli7Erin P. Demakos8Lewis R. Silverman9Ronald Hoffman10Mayo Clinic, Scottsdale, AZ, USACornell Weill Medical Center, New York, NY, USAMD Anderson Cancer Center, Houston, TX, USAIcahn School of Medicine at Mt. Sinai, New York, NY, USAGeorgetown University Medical Center, Washington, D.C., USAUniversity of Illinois School of Medicine, Chicago, IL, USANew York University School of Medicine, New York, NY, USAConsorzio Mario Negri Sud, Santa Maria Imbaro, ItalyIcahn School of Medicine at Mt. Sinai, New York, NY, USAIcahn School of Medicine at Mt. Sinai, New York, NY, USAIcahn School of Medicine at Mt. Sinai, New York, NY, USA The myeloproliferative neoplasm, myelofibrosis, is a morbid and frequently fatal illness encompassing primary myelofibrosis, and end-stage essential thrombocythemia and polycythemia. Bevacizumab (15 mg/kg intravenous (i.v.) every 21 days) was tested in a phase II international trial conducted by the Myeloproliferative Disorders Research Consortium. Thirteen patients were enrolled in the first stage of this 2-stage trial. Among the 11 patients who received therapy, only 3 received more than 4 cycles of therapy; none of the patients achieved an objective response. Furthermore, significant toxicity, not directly related to the vascular or gastrointestinal events typically associated with the anti-VEGF monoclonal antibody preparation in other disease states, was observed. Lack of objective responses coupled with toxicity led to the decision to terminate the study early. If future studies incor- porate bevacizumab in combination therapy for myelofibrosis, more modest doses should be considered. (clinicaltrials.gov Identifier 00667277). https://haematologica.org/article/view/12126 |
| spellingShingle | Ruben A. Mesa Richard T. Silver Srdan Verstovsek John Mascarenhas Craig M. Kessler Damiano Rondelli Judy D. Goldberg Roberto Marchioli Erin P. Demakos Lewis R. Silverman Ronald Hoffman Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial Haematologica |
| title | Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial |
| title_full | Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial |
| title_fullStr | Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial |
| title_full_unstemmed | Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial |
| title_short | Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial |
| title_sort | single agent bevacizumab for myelofibrosis results of the myeloproliferative disorders research consortium trial |
| url | https://haematologica.org/article/view/12126 |
| work_keys_str_mv | AT rubenamesa singleagentbevacizumabformyelofibrosisresultsofthemyeloproliferativedisordersresearchconsortiumtrial AT richardtsilver singleagentbevacizumabformyelofibrosisresultsofthemyeloproliferativedisordersresearchconsortiumtrial AT srdanverstovsek singleagentbevacizumabformyelofibrosisresultsofthemyeloproliferativedisordersresearchconsortiumtrial AT johnmascarenhas singleagentbevacizumabformyelofibrosisresultsofthemyeloproliferativedisordersresearchconsortiumtrial AT craigmkessler singleagentbevacizumabformyelofibrosisresultsofthemyeloproliferativedisordersresearchconsortiumtrial AT damianorondelli singleagentbevacizumabformyelofibrosisresultsofthemyeloproliferativedisordersresearchconsortiumtrial AT judydgoldberg singleagentbevacizumabformyelofibrosisresultsofthemyeloproliferativedisordersresearchconsortiumtrial AT robertomarchioli singleagentbevacizumabformyelofibrosisresultsofthemyeloproliferativedisordersresearchconsortiumtrial AT erinpdemakos singleagentbevacizumabformyelofibrosisresultsofthemyeloproliferativedisordersresearchconsortiumtrial AT lewisrsilverman singleagentbevacizumabformyelofibrosisresultsofthemyeloproliferativedisordersresearchconsortiumtrial AT ronaldhoffman singleagentbevacizumabformyelofibrosisresultsofthemyeloproliferativedisordersresearchconsortiumtrial |